Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKhanna, Navin-
dc.identifier.issn0975-0967 (Online); 0972-5849 (Print)-
dc.description.abstractDue to the technological advances made during the past decade, therapeutic monoclonal antibodies (MAbs) now represent an important and growing class of bio-therapeutics. Sales of MAbs are increasing rapidly from virtually nil in 1996 to potentially over $ 1 billion in 2001. With the potential new targets resulting from genomics and with methods now in place to make fully human antibodies, the potential of antibodies as valuable therapeutics in oncology, inflammation and cardiovascular disease is being fully realised. There are 235 MAbs under different stages of development. More than 100 clinical trials are in progress, 14 of them in phase III (mostly for cancer diagnosis and therapy). To meet the increased demand of the monoclonals, worldwide manufacturing capacity for MAbs must increase dramatically, during the next few years, if the industry segment is to avoid a manufacturing bottleneck. Many novel expression strategies are being evaluated to increase the production capacity. Factors including molecular fidelity and cost of products will be critical in the selection of the expression systems.en_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJBT Vol.01(1) [January 2002]en_US
dc.subjectMonoclonal antibodiesen_US
dc.subjectMab technologiesen_US
dc.titleTherapeutic Monoclonal Antibodies: Attractions and Challengesen_US
Appears in Collections: IJBT Vol.01(1) [January 2002]

Files in This Item:
File Description SizeFormat 
IJBT 1(1) 50-57.pdf2.09 MBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.